Comments on: Spotlight on Zolgensma: REGENXBIO receives $80m from Novartis for AAV vector /features/zolgensma-regenxbio-novartis/ The leading site for news and procurement in the pharmaceutical industry Wed, 23 Mar 2022 10:23:07 +0000 hourly 1 https://wordpress.org/?v=6.7.2